Latest News
Alzheimer’s Disease Research, a BrightFocus Foundation program, was on the ground at the 2024 Alzheimer’s Association International Conference (AAIC) in Philadelphia to share insights on the latest research and foster scientific collaboration. Catch up on a few of the top headlines from AAIC.
A new BrightFocus-funded study of cognitively healthy 100-year-olds sheds light on genetic characteristics that protect the brain.
In This Issue:
- President’s Corner
- Alzheimer’s Drugs in the News
- Researcher Spotlight: Matthew Isaacson, PhD
- And More!
Another disease-modifying Alzheimer's therapy hits the market.
On June 10, the Food and Drug Administration’s Peripheral and Central Nervous System Drugs Advisory Committee unanimously voted that Eli Lilly’s Alzheimer’s drug, donanemab, is effective for treating early symptomatic Alzheimer’s disease.
In response to overwhelming interest in its first six episodes, four additional episodes of Zoom In on Dementia & Alzheimer’s will walk participants through specific Alzheimer’s clinical trials and research studies.
A new BrightFocus-funded study found that identifying disruptive sleep patterns may help identify people at risk of Alzheimer’s disease up to seven years prior to end of life.
In This Issue:
- President’s Corner
- Exercise-Induced Hormone Could Treat Alzheimer’s Disease
- Researcher Spotlight: Ariel Gilad, PhD
- Tips for Managing Caregiver Stress
- Zoom In on Dementia & Alzheimer’s
- Help Fight Alzheimer’s Through a Will or Bequest
A promising new treatment for individuals suffering from stroke, concussion, and traumatic brain injury, known risk factors for dementia, has received approval from the U.S. Food & Drug Administration to move into Phase 2 clinical trials. Learn more.
Learn how our funded scientists are advancing new ways of diagnosing Alzheimer’s disease earlier and more accurately.
